Motor Neuron Disease
Make a Difference
PLEASE NOTE:
As of November 23, 2009, ALS Canada has a new address and phone number:
3000 Steeles Avenue East, Suite 200
Markham, Ontario L3R 4T9
Phone: 905-248-2052   Fax: 905-248-2019

Motor Neuron Disease

Motor neuron disease (MNDS) is a progressive, degenerative disorder that affects nerves in the upper or lower parts of the body. Most of the time motor neuron diseases are acquired, but approximately five to ten per cent of the time the disease is hereditary. The following diseases are classified as a motor neuron disease:

  • Amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease)
  • Progressive muscular atrophy
  • Postpolio syndrome

Motor neuron disease usually occurs in people between the ages of 40-70 with the average at 55. There have been a few cases where onset has started as early as in the teens. The diagnosis of MND is made from a physical examination, an EMG study and a pattern of finding and excluding other diseases which allows the neurologist to establish a diagnosis and to determine which form of the disease is present.

Unfortunately, there is not a specific test available which gives a "yes" or "no" answer. Symptoms may include difficulty swallowing, limb weakness, slurred speech, impaired gait, facial weakness, and muscle cramps. Respiration problems may occur but this usually happens in the later stages of the disease.

The cause(s) of most MNDs are unknown, but environmental, toxic, viral, or genetic factors may be implicated. Currently, treatment options include, physical therapy, drug therapy, and assistive devices may help some people. The prognosis for people living with a MND varies depending on the type, for some—such as people with ALS—the outcome is terminal.

At this time there is no cure for motor neuron disease. There is one medication available by prescription —Rilutek— which has shown in clinical trials to slow the progression of ALS slightly. Over the last ten years it appears that people with MNDs are living longer because of improved care and increased knowledge of the disease.

ALS Research News - The latest ALS als research articles.
1.  Study Links Neurodegeneration in Head Trauma and ALS

Nearly four years since researchers identified the mystery component of toxic protein aggregates in ALS and frontotemporal lobar degeneration (FTLD)-affected motor neurons as TAR DNA-binding protein ( ◊

"Study Links Neurodegeneration in Head Trauma and ALS"
2.  New Genes, Proteins and Biomarkers

Buried deep within thick skulls and boney spines, the neurons of the central nervous system are, perhaps, the most protected cells of the body. This is good news for healthy neurons, but bad news for ◊

"New Genes, Proteins and Biomarkers"
3.  A clinical study of Ceftriaxone in ALS

A clinical study of Ceftriaxone in ALS. ◊

"A clinical study of Ceftriaxone in ALS"
4.  ALS Vaccine To Target Misfolded SOD1

Mutations in the gene encoding superoxide dismutase cause approximately 20 per cent of familial ALS cases, according to a paper recently published in Human Molecular Genetics. ◊

"ALS Vaccine To Target Misfolded SOD1"
5.  Is BMAA a neurotoxin relevant to ALS?

Cyanobacteria, also known as the blue-green algae that smother ponds, lakes and seas around the world, produce several toxins. Among them is beta-methylamino-L-alanine (BMAA), an amino acid that some ◊

"Is BMAA a neurotoxin relevant to ALS?"
6.  Neurodegenerative Disease Research Accelerates

While scientists worldwide strive to understand neurodegeneration and find ways to slow or stop it, variations in how they perform experiments and interpret their findings can slow the global effort t ◊

"Neurodegenerative Disease Research Accelerates"
7.  ALSUntangled investigates stem cell transplants in Mexico and Germany

Although stem cell transplants might eventually represent an effective treatment for ALS, many challenges need to be overcome, such as how to deliver the cells into motor areas throughout the nervous ◊

"ALSUntangled investigates stem cell transplants in Mexico and Germany"
8.  Guidelines for preclinical animal research

We know more about the biology underlying ALS than ever before, but little of this knowledge has been translated into effective treatments for patients. ◊

"Guidelines for preclinical animal research"